Identification of Selected in vitro-Generated Phase-I Metabolites of the Steroidal Selective Androgen Receptor Modulator MK-0773 for Doping Control Purposes

Research into developing anabolic agents for various therapeutic purposes has been pursued for decades. As the clinical utility of anabolic–androgenic steroids has been found to be limited because of their lack of tissue selectivity and associated off-target effects, alternative drug entities have been designed and are commonly referred to as selective androgen receptor modulators (SARMs). While most of these SARMs are of nonsteroidal structure, the drug candidate MK-0773 comprises a 4-aza-steroidal nucleus. Besides the intended therapeutic use, SARMs have been found to be illicitly distributed and misused as doping agents in sport, necessitating frequently updated doping control analytical assays. As steroidal compounds reportedly undergo considerable metabolic transformations, the phase-I metabolism of MK-0773 was simulated using human liver microsomal (HLM) preparations and electrochemical conversion. Subsequently, major metabolic products were identified and characterized employing liquid chromatography—high-resolution/high-accuracy tandem mass spectrometry with electrospray (ESI) and atmospheric pressure chemical ionization (APCI) as well as nuclear magnetic resonance (NMR) spectroscopy. MK-0773 produced numerous phase-I metabolites under the chosen in vitro incubation reactions, mostly resulting from mono- and bisoxygenation of the steroid. HLM yielded at least 10 monooxygenated species, while electrochemistry-based experiments resulted predominantly in three monohydroxylated metabolites. Elemental composition data and product ion mass spectra were generated for these analytes, ESI/APCI measurements corroborated the formation of at least two N-oxygenated metabolites, and NMR data obtained from electrochemistry-derived products supported structures suggested for three monohydroxylated compounds. Hereby, the hydroxylation of the A-ring located N-bound methyl group was found to be of particular intensity. In the absence of controlled elimination studies, the produced information enables the implementation of new target analytes into routine doping controls and expands the focus of anti-doping efforts concerning this new anabolic agent.

[1]  P. Jadhav,et al.  2-Chloro-4-[[(1R,2R)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy. , 2016, Journal of medicinal chemistry.

[2]  B. Lee,et al.  Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids , 2015, Expert opinion on drug safety.

[3]  M. Thevis,et al.  Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing. , 2015, Rapid communications in mass spectrometry : RCM.

[4]  T. Hitaka,et al.  Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part I. , 2015, Bioorganic & medicinal chemistry.

[5]  M. Thevis,et al.  In vitro Metabolism Studies on the Selective Androgen Receptor Modulator LG121071 and its Implementation into Human Doping Controls Using Liquid Chromatography-Mass Spectrometry , 2015, European journal of mass spectrometry.

[6]  D. Powell,et al.  1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile derivatives as potent and tissue selective androgen receptor modulators. , 2014, Journal of medicinal chemistry.

[7]  A. Dobs,et al.  Enobosarm (GTx-024, S-22): a potential treatment for cachexia. , 2014, Future oncology.

[8]  Frederick C W Wu,et al.  Androgen effects on skeletal muscle: implications for the development and management of frailty , 2014, Asian journal of andrology.

[9]  D. Papanicolaou,et al.  A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia , 2013, The journal of nutrition, health & aging.

[10]  Z. Sui,et al.  Deciphering the selective androgen receptor modulators paradigm , 2013, Expert opinion on drug discovery.

[11]  D. Herndon,et al.  Burns: an update on current pharmacotherapy , 2012, Expert opinion on pharmacotherapy.

[12]  T. Prangé,et al.  Discovery of diarylhydantoins as new selective androgen receptor modulators. , 2012, Journal of medicinal chemistry.

[13]  N. Triballeau,et al.  Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator. , 2012, Journal of medicinal chemistry.

[14]  F. Martin,et al.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? , 2012, Endocrine reviews.

[15]  U. Karst,et al.  Simulation of the oxidative metabolism of diclofenac by electrochemistry/(liquid chromatography/)mass spectrometry , 2012, Analytical and Bioanalytical Chemistry.

[16]  M. Thevis,et al.  Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes. , 2011, Journal of mass spectrometry : JMS.

[17]  U. Karst,et al.  Online electrochemistry/mass spectrometry in drug metabolism studies: principles and applications , 2010, Expert opinion on drug metabolism & toxicology.

[18]  P. Hodor,et al.  Discovery of the Selective Androgen Receptor Modulator MK-0773 Using a Rational Development Strategy Based on Differential Transcriptional Requirements for Androgenic Anabolism Versus Reproductive Physiology* , 2010, The Journal of Biological Chemistry.

[19]  Ramesh Narayanan,et al.  Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit. , 2009, Journal of medicinal chemistry.

[20]  U. Karst,et al.  Metabolic studies of tetrazepam based on electrochemical simulation in comparison to in vivo and in vitro methods. , 2009, Journal of chromatography. A.

[21]  M. Thevis,et al.  Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. , 2006, Rapid communications in mass spectrometry : RCM.

[22]  Chowdhury,et al.  Liquid chromatography/mass spectrometry methods for distinguishing N-oxides from hydroxylated compounds , 2000, Analytical chemistry.

[23]  Duane D. Miller,et al.  Discovery of nonsteroidal androgens. , 1998, Biochemical and biophysical research communications.

[24]  A. Q. Maisel The hormone quest , 1965 .